Key Details
Price
$86.59Annual ROE
-22.39%Beta
0.73Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2024 Earnings Conference Call October 30, 2024 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Founder, Chairman and CEO Mark Neumann - EVP and CCO Sanjeev Narula - CFO Suresh Durgam - EVP and CMO Conference Call Participants Andrew Tsai - Jefferies Jessica Fye - JPMorgan Charles Duncan - Cantor Jason Gerberry - Bank of America Securities Jeff Hung - Morgan Stanley Michael DiFiore - Evercore David Amsellem - Piper Sandler Joel Beatty - Baird Corinne Johnson - Goldman Sachs Operator Good day and thank you for standing by. Welcome to Intra-Cellular Therapies 3Q 2024 Earnings Conference Call.
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase
Intra-Cellular reports mixed third-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)
Intra-Cellular (ITCI) reported earnings 30 days ago. What's next for the stock?
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:
This biotech stock is in a base and seeking support at a moving average. The company's losses are dwindling and analysts see profits coming.
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
FAQ
- What is the primary business of Intra-Cellular Therapies?
- What is the ticker symbol for Intra-Cellular Therapies?
- Does Intra-Cellular Therapies pay dividends?
- What sector is Intra-Cellular Therapies in?
- What industry is Intra-Cellular Therapies in?
- What country is Intra-Cellular Therapies based in?
- When did Intra-Cellular Therapies go public?
- Is Intra-Cellular Therapies in the S&P 500?
- Is Intra-Cellular Therapies in the NASDAQ 100?
- Is Intra-Cellular Therapies in the Dow Jones?
- When was Intra-Cellular Therapies's last earnings report?
- When does Intra-Cellular Therapies report earnings?
- Should I buy Intra-Cellular Therapies stock now?